Clene (CLNN) Director Matthew Kiernan Receives Option Award

What Happened Matthew Kiernan, a director of Clene Inc. (CLNN), was granted options for 2,755 shares of common stock on February 19, 2026. The grant was reported as a derivative acquisition with no cash paid at grant ($0.00 reported). Per the filing footnote, the options carry an exercise price of $4.73 per share and vest immediately upon grant.

Key Details

• Transaction date: 2026-02-19 (reported on Form 4 filed 2026-02-20).
• Transaction type: Award/grant of options (derivative); acquisition reported at $0.00.
• Option terms noted: 2,755 share options, exercise price $4.73, immediate vesting (granted under Clene’s Amended 2020 Stock Plan).
• Shares owned after transaction: not specified in the provided filing details.
• Timeliness: Filed the next day (appears timely); no late filing indicated.

Context This was an option grant (a compensation award), not a stock purchase or sale. No shares were exercised or sold in this transaction — exercising later would require payment of the $4.73 per-share exercise price. Option grants to directors are commonly part of compensation and do not by themselves indicate buying or selling sentiment.